| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| IMTXImmatics N.V. | 1.33B | 9.92 | 70.86 | 188.6% | -136.72% | -27.81% | 0.03 | |
| CTMXCytomX Therapeutics, Inc. | 720.1M | 4.25 | 11.18 | 36.45% | 24.66% | 26.09% | ||
| IOVAIovance Biotherapeutics, Inc. | 881.27M | 2.22 | -1.73 | 136.99% | -158.78% | -56.62% | 0.08 | |
| REPLReplimune Group, Inc. | 572.64M | 7.30 | -2.38 | -117.82% | 0.18 | |||
| NKTRNektar Therapeutics | 719.28M | 35.36 | -4.07 | 9.22% | -192.87% | -141.9% | 1.69 | |
| IMNMImmunome, Inc. | 2.52B | 22.85 | -4.57 | -35.5% | -23.01% | -84.4% | 0.03 | |
| IBRXImmunityBio, Inc. | 3.89B | 3.95 | -6.37 | 22.71% | -422.28% | |||
| NRIXNurix Therapeutics, Inc. | 1.91B | 18.86 | -6.55 | -29.15% | -292.5% | -65.76% | 0.05 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Sales/Revenue | 85K | 394K | 2.29M | 3.29M | 1.98M | 0 |
| Revenue Growth % | - | 3.64% | 4.81% | 0.43% | -0.4% | -1% |
| Cost of Goods Sold | 14.52M | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | 170.87% | - | - | - | - | - |
| Gross Profit | -14.44M | 394K | 2.29M | 3.29M | 1.98M | 0 |
| Gross Margin % | -169.87% | 1% | 1% | 1% | 1% | - |
| Gross Profit Growth % | - | 1.03% | 4.81% | 0.43% | -0.4% | -1% |
| Operating Expenses | 7.39M | 25.09M | 42.74M | 65.37M | 94.7M | 61.04M |
| OpEx % of Revenue | 86.96% | 63.68% | 18.65% | 19.89% | 47.88% | - |
| Selling, General & Admin | 7.34M | 9.3M | 21.25M | 37.63M | 34.87M | 23.51M |
| SG&A % of Revenue | 86.39% | 23.61% | 9.28% | 11.45% | 17.63% | - |
| Research & Development | 14.52M | 15.96M | 21.96M | 28.14M | 32.15M | 34.36M |
| R&D % of Revenue | 170.87% | 40.5% | 9.58% | 8.57% | 16.25% | - |
| Other Operating Expenses | 0 | -172K | -470K | -408K | 27.69M | 3.17M |
| Operating Income | -21.78M | -24.69M | -40.45M | -62.08M | -92.73M | -61.04M |
| Operating Margin % | -256.26% | -62.68% | -17.65% | -18.89% | -46.88% | - |
| Operating Income Growth % | - | -0.13% | -0.64% | -0.53% | -0.49% | 0.34% |
| EBITDA | -21.36M | -22.71M | -37.44M | -58.16M | -87.3M | -55.19M |
| EBITDA Margin % | -251.24% | -57.64% | -16.34% | -17.7% | -44.13% | - |
| EBITDA Growth % | - | -0.06% | -0.65% | -0.55% | -0.5% | 0.37% |
| D&A (Non-Cash Add-back) | 427K | 1.99M | 3.01M | 3.92M | 5.43M | 5.85M |
| EBIT | -21.78M | -24.69M | -40.45M | -62.08M | -66.77M | -60.73M |
| Net Interest Income | 674K | 88K | 11K | 1.7M | 2.86M | 0 |
| Interest Income | 674K | 88K | 11K | 1.7M | 2.86M | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 625K | 4.83M | -14.87M | 12.42M | 9.32M | 8.25M |
| Pretax Income | -21.16M | -19.86M | -55.32M | -49.66M | -83.41M | -52.79M |
| Pretax Margin % | -248.91% | -50.41% | -24.15% | -15.11% | -42.17% | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1.17% | 0.85% | 1% |
| Net Income | -21.16M | -19.86M | -55.32M | -58.21M | -71.06M | -52.79M |
| Net Margin % | -248.91% | -50.41% | -24.15% | -17.71% | -35.92% | - |
| Net Income Growth % | - | 0.06% | -1.79% | -0.05% | -0.22% | 0.26% |
| Net Income (Continuing) | -21.16M | -19.86M | -55.32M | -49.66M | -83.41M | -52.79M |
| Discontinued Operations | 0 | 0 | 0 | -8.54M | 12.35M | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -15.57 | -4.55 | -12.67 | -13.25 | -20.94 | -11.49 |
| EPS Growth % | - | 0.71% | -1.78% | -0.05% | -0.58% | 0.45% |
| EPS (Basic) | -15.57 | -4.55 | -12.67 | -13.25 | -20.94 | -11.49 |
| Diluted Shares Outstanding | 1.36M | 4.37M | 4.37M | 4.39M | 4.44M | 4.6M |
| Basic Shares Outstanding | 1.36M | 4.37M | 4.37M | 4.39M | 4.44M | 4.6M |
| Dividend Payout Ratio | - | - | - | - | - | - |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 18.76M | 31.71M | 58.75M | 102.58M | 71.2M | 58.96M |
| Cash & Short-Term Investments | 17.83M | 30.54M | 56.03M | 98.56M | 35.93M | 48.28M |
| Cash Only | 5.3M | 30.54M | 56.03M | 57.62M | 35.93M | 48.28M |
| Short-Term Investments | 12.53M | 0 | 0 | 40.94M | 0 | 0 |
| Accounts Receivable | 78K | 317K | 483K | 626K | 17.7M | 1.8M |
| Days Sales Outstanding | 334.94 | 293.67 | 76.95 | 69.53 | 3.27K | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 853K | 830K | 1.43M | 1.52M | 237K | 584K |
| Total Non-Current Assets | 16.59M | 16.64M | 37.95M | 78.21M | 48.28M | 38.88M |
| Property, Plant & Equipment | 16.59M | 16.14M | 33.08M | 74.55M | 41.61M | 35.24M |
| Fixed Asset Turnover | 0.01x | 0.02x | 0.07x | 0.04x | 0.05x | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 3.26M | 3.37M | 4.64M | 0 |
| Other Non-Current Assets | -16.59M | 497K | 1.62M | 293K | 2.03M | 3.64M |
| Total Assets | 35.84M | 48.34M | 96.7M | 180.79M | 119.48M | 97.84M |
| Asset Turnover | 0.00x | 0.01x | 0.02x | 0.02x | 0.02x | - |
| Asset Growth % | - | 0.35% | 1% | 0.87% | -0.34% | -0.18% |
| Total Current Liabilities | 4.31M | 4.87M | 14.54M | 18.05M | 12.67M | 13.15M |
| Accounts Payable | 1.2M | 914K | 5.19M | 2.27M | 1.25M | 1.45M |
| Days Payables Outstanding | 30.08 | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 1.74M | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 1000K | 799K | 989K | 660K |
| Other Current Liabilities | 3.11M | 2.37M | 3.29M | 9.26M | 3.94M | 2.55M |
| Current Ratio | 4.36x | 6.52x | 4.04x | 5.68x | 5.62x | 4.49x |
| Quick Ratio | 4.36x | 6.52x | 4.04x | 5.68x | 5.62x | 4.49x |
| Cash Conversion Cycle | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 102.19M | 21.78M | 35.48M | 39.9M | 59.05M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 12.53M | 20.99M | 35.1M | 33.54M | 28.89M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 89.66M | 619K | 373K | 6.36M | 30.16M |
| Total Liabilities | 17.88M | 107.06M | 36.33M | 53.53M | 52.57M | 72.19M |
| Total Debt | 0 | 14.05M | 22.73M | 37.09M | 37.67M | 33.64M |
| Net Debt | -5.3M | -16.49M | -33.3M | -20.53M | 1.74M | -14.64M |
| Debt / Equity | - | - | 0.38x | 0.29x | 0.56x | 1.31x |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - |
| Total Equity | 17.96M | -58.71M | 60.38M | 127.26M | 66.91M | 25.65M |
| Equity Growth % | - | -4.27% | 2.03% | 1.11% | -0.47% | -0.62% |
| Book Value per Share | 13.22 | -13.45 | 13.83 | 28.96 | 15.08 | 5.58 |
| Total Shareholders' Equity | 17.96M | -58.71M | 60.38M | 127.26M | 66.91M | 25.65M |
| Common Stock | 1K | 1K | 0 | 4K | 5K | 1K |
| Retained Earnings | -39.9M | -59.76M | -115.08M | -173.29M | -244.34M | -297.13M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 1K | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Cash from Operations | -18.38M | -24.17M | -34.63M | -34.9M | -52.4M | -41.4M |
| Operating CF Margin % | -216.21% | -61.35% | -15.12% | -10.62% | -26.49% | - |
| Operating CF Growth % | - | -0.32% | -0.43% | -0.01% | -0.5% | 0.21% |
| Net Income | -21.16M | -19.86M | -55.32M | -58.22M | -71.06M | -52.79M |
| Depreciation & Amortization | 1.4M | 1.99M | 3.01M | 3.92M | 5.43M | 5.85M |
| Stock-Based Compensation | 205K | 272K | 2.29M | 16.39M | 9.67M | 1.75M |
| Deferred Taxes | -329K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 1.38M | -4.79M | 14.76M | -10.89M | -1.1M | -256K |
| Working Capital Changes | 124K | -1.77M | 615K | 13.9M | 4.67M | 4.04M |
| Change in Receivables | 124K | -10K | -395K | -131K | -929K | -727K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | -324K | -617K | 186K | -290K | 797K |
| Cash from Investing | 3.75M | 11.36M | -5.54M | -81.96M | 30.08M | 34K |
| Capital Expenditures | -2M | -1.16M | -5.54M | -41.37M | -12.04M | -26K |
| CapEx % of Revenue | 23.48% | 2.95% | 2.42% | 12.59% | 6.09% | - |
| Acquisitions | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - |
| Other Investing | 5.75M | 0 | 0 | 0 | 105K | 60K |
| Cash from Financing | 14.01M | 38.05M | 68.44M | 118.55M | 779K | 53.73M |
| Debt Issued (Net) | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - |
| Other Financing | 14.01M | 51K | 1.48M | 112.65M | 375K | 4.67M |
| Net Change in Cash | - | - | - | - | - | - |
| Free Cash Flow | -20.37M | -25.33M | -40.18M | -76.27M | -64.43M | -41.42M |
| FCF Margin % | -239.69% | -64.3% | -17.54% | -23.21% | -32.57% | - |
| FCF Growth % | - | -0.24% | -0.59% | -0.9% | 0.16% | 0.36% |
| FCF per Share | -15.00 | -5.80 | -9.20 | -17.35 | -14.52 | -9.01 |
| FCF Conversion (FCF/Net Income) | 0.87x | 1.22x | 0.63x | 0.60x | 0.74x | 0.78x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -117.77% | - | -6652.92% | -62.04% | -73.19% | -114.06% |
| Return on Invested Capital (ROIC) | - | - | - | -69.6% | -79.31% | -114.93% |
| Gross Margin | -16987.06% | 100% | 100% | 100% | 100% | - |
| Net Margin | -24890.59% | -5041.12% | -2414.62% | -1771.45% | -3592.42% | - |
| Debt / Equity | - | - | 0.38x | 0.29x | 0.56x | 1.31x |
| FCF Conversion | 0.87x | 1.22x | 0.63x | 0.60x | 0.74x | 0.78x |
| Revenue Growth | - | 363.53% | 481.47% | 43.43% | -39.81% | -100% |
| 2022 | |
|---|---|
| License | 800K |
| License Growth | - |
Senti Biosciences, Inc. (SNTI) saw revenue decline by 100.0% over the past year.
Senti Biosciences, Inc. (SNTI) reported a net loss of $47.6M for fiscal year 2024.
Senti Biosciences, Inc. (SNTI) has a return on equity (ROE) of -114.1%. Negative ROE indicates the company is unprofitable.
Senti Biosciences, Inc. (SNTI) had negative free cash flow of $50.3M in fiscal year 2024, likely due to heavy capital investments.